SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis quarterly earnings report and forward guidance are the dominant focus, with traders watching whether growth and an improved outlook can change the stocks weak performance. Sentiment is sharply divided: some expect a rebound on strong results, while others fear another selloff even if the company beats expectations, citing past post-earnings declines and concerns about guidance.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas strong quarterly results and sharply raised outlook, including an ambitious 2027 revenue forecast, are driving attention amid demand for AI data-center hardware and networking. Bulls see the report as evidence the buildout remains robust, while skeptics point to margin and cash-flow concerns, high expectations, and volatile trading after a steep pullback.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak quarterly results, sharply reduced earnings outlook, and dividend suspension are driving attention, with management citing recession-level appliance demand and prioritizing debt reduction. Traders are split between fears over the balance sheet and a prolonged downturn, and bargain-hunting hopes for a rebound; many also question managements explanation and execution.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XPs sharp selloff is being linked to a broad rout in Brazilian assets after Lulas reelection, amid trader concerns about government spending, fiscal discipline and the currency. Many traders call the drop an overreaction and look for a rebound, while others warn that political and macroeconomic risks could keep pressure on the shares.

StoneCo Ltd. engages in the provision of financial technology solutions. It caters to merchants and partners that conduct electronic commerce across in-store, online, and mobile channels. The firm offers cloud-based technology platform, electronic payments, and automation of business processes at the point-of-sale. The company was founded by André Street de Aguiar in 2000 and is headquartered in São Paulo, Brazil.

StoneCo Ltd - Ordinary Shares - Class A

StoneCo Ltd

StoneCo is caught in a sharp selloff across Brazilian stocks after Lulas election win, as traders worry about fiscal discipline and the outlook for Brazilian assets. Some see the drop as an overreaction and a buying opportunity, while others are wary of further losses and are waiting for the market to find a floor.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Reported advanced acquisition talks with DoorDash are driving attention, with traders weighing the prospect of a takeover premium against claims that the offer undervalues Instacart and concerns that talks could fall through. No definitive deal has been announced.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

CEO John Giamatteos CNBC appearance highlighting QNXs expansion into physical AI and robotics, Alloy Kore, and its Nvidia collaboration is driving attention. Bulls see potential for BlackBerrys growth story to gain recognition, while skeptics question adoption and cite insider selling and market volatility.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention as small caps show resilience and traders debate whether recent strength signals a rotation out of AI and megacap tech. Some see easing-yield expectations and a potential catch-up rally as supportive, while others warn that weak breadth, technical resistance, and oil and Fed uncertainty could leave the bounce vulnerable.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is drawing attention ahead of its quarterly results, with traders focused on branded-checkout growth, margins and guidance; bearish voices fear another post-earnings drop and continued competitive pressure, while bulls point to subdued expectations and potential growth from Venmo and advertising. Takeover and bank-charter speculation is also circulating, but remains unconfirmed.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Reports that Volkswagen is weighing Xpeng-developed software for many European models have raised concern among traders about the RivianVW software partnership, as RIVN sinks to fresh 52-week lows. The discussion is also focused on upcoming quarterly results: bearish views cite cash burn and uncertain profitability, while some traders are buying the dip and looking for evidence of improving deliveries or margins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Companies Pushing Experimental Treatments Toward Their Biggest Tests

These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.

ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firms Securities Investigation Following 47.3% Share Drop

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma (Arrivent or the Company) (NASDAQ: AVBP) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & KorsinskyPR NewswireNEW YORK, Oct. 13, 2026ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead...

AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. (ArriVent or the Company) (NASDAQ: AVBP) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma

AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharmaPR NewswireNEW YORK, Oct. 7, 2026AVBP was down 56.7...

ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)

ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP) ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)PR NewswireNEW YORK, Oct. 6...

ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.read more...

AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’

Equity

ArriVent BioPharma’s experimental lung cancer treatment failed to meet its primary endpoint in a Phase 3 trial.

ArriVent BioPharma (NASDAQ:AVBP) Upgraded at Truist Financial

Truist Financial upgraded ArriVent BioPharma to a "strong-buy" rating in a research note on Monday...

ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-arrivent-biopharma-inc-stock...

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, licensing, and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

ArriVent BioPharma Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>Firmonertinib did not significantly improve progression-free survival compared with chemotherapy.</li><li>The 240 mg dose produced a 60% confirmed response rate, compared to 33% for chemotherapy.</li><li>The company continues to test the drug in a separate Phase 3 trial</li></ul>Shares of ArriVent BioPharma (AVBP) crashed over 48% to a record low on Tuesday after the biotech company said its experimental lung-cancer treatment failed to meet the main goal of a Phase 3 trial.<a href="https://stocktwits.com/symbol/AVBP">AVBP stock</a> also clocked its biggest ever single-day slump.<h2 class="st-heading-2">Firmonertinib Misses Main Goal</h2>The Phase 3 Furvent study tested Firmonertinib as a first-line treatment for patients with advanced non-small cell lung cancer with mutations, a difficult-to-treat form of the disease. The study’s primary endpoint was progression-free survival, or how long patients lived without their cancer worsening, as assessed by an independent review committee.Patients receiving the higher 240 mg dose had median progression-free survival of 11 months, compared with 9.5 months for chemotherapy. However, the result did not reach statistical significance.However, the 240 mg dose produced a 60% confirmed response rate, compared to 33% for chemotherapy.<h2 class="st-heading-2">Firmonertinib To Be Developed In A Different Trial</h2>Firmonertinib has already received Breakthrough Therapy and Orphan Drug designations in the U.S. and is approved in China for several&nbsp;EGFR-mutant lung cancer indications.The company said it is reviewing the full Furvent dataset before deciding the program’s next steps. The company continues to test the drug in a separate Phase 3 trial.<h2 class="st-heading-2">What’s In The Pipeline?</h2>Beyond lung cancer, ArriVent is developing ARR-217 for gastrointestinal cancers. The drug is currently in Phase 1b dose optimization. It is also developing ARR-002, an experimental therapy for ovarian and endometrial cancers that received U.S. Food and Drug Administration (FDA) clearance to begin human testing in May.ArriVent ended June with $373.1 million in cash and investments, up from $312.8 million at the end of 2025. Management said the balance should be sufficient to fund operations through 2028.<h2 class="st-heading-2">Retail Turns Extremely Bullish</h2>Despite the slump, retail sentiment surrounding AVBP on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/AVBP_9ca983d356.png" alt="AVBP.png">One user said the stock was “way undervalued.”<stembedurl>https://stocktwits.com/Nitish_mahajan2/message/665857233</stembedurl>Another user expects the stock to climb to at least $17 by the end of the session. It is currently trading at around $14.8.<stembedurl>https://stocktwits.com/Fa07/message/665859832</stembedurl>The stock is down around 30% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-rallies-20-in-three-sessions-why-does-goldman-see-another-30-upside/cZDtaf1RBlJ">SPCX Stock Rallies 20% In Three Sessions – Why Does Goldman See Another 30% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

SPDR S&P Biotech ETF

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$15.36
Prev Close	$21.00
Open	$18.14
Dividend Yield	0.00%
50-Day Moving Average	$25.88
Beta	0.91
Avg. Volume	637,138.80
PE Ratio	-4.17

52-Week High	$35.83
52-Week Low	$11.36
Market Capitalization	$1.04B
EPS (Annual)	-$4.32
Price to Book	2.02
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVBP Fundamentals